Isolation and characterization of multidrug-resistant side population cells in prostate carcinoma

被引:0
作者
Wang, Yu-qiu [1 ]
Tian, He [1 ]
Yang, Tong-ju [1 ]
Liu, Li [1 ]
机构
[1] Peoples Hosp Zoucheng City, Dept Pharm, Zoucheng 273500, Shandong, Peoples R China
关键词
Side population cells; ABC transporters; Cancer stem cells; Chemotherapy; Prostate treatment failure; Tumor recurrence; Drug resistance; CANCER STEM-CELLS; IDENTIFICATION; EXPRESSION; BINDING; EFFLUX; LINE;
D O I
10.4314/tjpr.v15i11.9
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Purpose: To isolate and characterize cancer stem-like side population (SP) cells from prostate cancer tissues using Hoechst 33342 dye exclusion. Methods: The presence of SP cells was analyzed in tumor samples by fluorescence activated cell sorting. The cell survival rate and ability for cell self-renewal using the sphere formation assay were evaluated after treatment with multiple drugs. Results: SP cells in the prostate cancer samples constituted 2.8 %, but fell to 0.6 % after treatment with verapamil. The SP cells showed high resistance to drugs such as 5-fluorouracil, cisplatin, paclitaxel (2 mu mol/L) and oxaliplatin. The survival rate of SP cells after treatment with these drugs was significantly higher (p < 0.01) than that of non-SP cells. Furthermore, the number of spheres generated in serum-free medium was significantly higher in prostate cancer SP cells than in non-SP cells. Conclusion: The presence of SP cells is responsible for prostate treatment failure and tumor recurrence. Therefore, isolation and characterization of SP cells may provide new insights into the development of novel therapeutic agents targeting cancer stem cells for complete eradication of the tumor.
引用
收藏
页码:2357 / 2363
页数:7
相关论文
共 18 条
  • [1] [Anonymous], 2002, INT ETH GUID BIOM RE
  • [2] Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer
    Bapat, SA
    Mali, AM
    Koppikar, CB
    Kurrey, NK
    [J]. CANCER RESEARCH, 2005, 65 (08) : 3025 - 3029
  • [3] Hyaluronan-CD44 interaction activates stem cell marker Nanog, Stat-3-mediated MDR1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells
    Bourguignon, Lilly Y. W.
    Peyrollier, Karine
    Xia, Weiliang
    Gilad, Eli
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2008, 283 (25) : 17635 - 17651
  • [4] Gao AC, 1998, CANCER RES, V58, P2350
  • [5] Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo
    Goodell, MA
    Brose, K
    Paradis, G
    Conner, AS
    Mulligan, RC
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 183 (04) : 1797 - 1806
  • [6] Isolation and Characterization of Cancer Stem Cells from High-Grade Serous Ovarian Carcinomas
    He, Qi-zhi
    Luo, Xue-zhen
    Wang, Kai
    Zhou, Qian
    Ao, Hong
    Yang, Yan
    Li, Shu-xia
    Li, Ying
    Zhu, Hui-ting
    Duan, Tony
    [J]. CELLULAR PHYSIOLOGY AND BIOCHEMISTRY, 2014, 33 (01) : 173 - 184
  • [7] A distinct "side population" of cells with high drug efflux capacity in human tumor cells
    Hirschmann-Jax, C
    Foster, AE
    Wulf, GG
    Nuchtern, JG
    Jax, TW
    Gobel, U
    Goodell, MA
    Brenner, MK
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (39) : 14228 - 14233
  • [8] Cancer statistics, 2008
    Jemal, Ahmedin
    Siegel, Rebecca
    Ward, Elizabeth
    Hao, Yongping
    Xu, Jiaquan
    Murray, Taylor
    Thun, Michael J.
    [J]. CA-A CANCER JOURNAL FOR CLINICIANS, 2008, 58 (02) : 71 - 96
  • [9] 213Bi-PAI2 conjugate selectively induces apoptosis in PC3 metastatic prostate cancer cell line and shows anti-cancer activity in a xenograft animal model
    Li, Y
    Rizvi, SMA
    Ranson, M
    Allen, BJ
    [J]. BRITISH JOURNAL OF CANCER, 2002, 86 (07) : 1197 - 1203
  • [10] Cancer stem-like cells can be isolated with drug selection in human ovarian cancer cell line SKOV3
    Ma, Li
    Lai, Dongmei
    Liu, Te
    Cheng, Weiwei
    Guo, Lihe
    [J]. ACTA BIOCHIMICA ET BIOPHYSICA SINICA, 2010, 42 (09) : 593 - 602